ScanCer - Breast Cancer Medicine Screening

Project

ScanCer

An ATP-FRET probe for high-throughput screening of breast cancer medicines

Prevalence

Breast cancer accounts for about 30% of all new female cancers each year.

Breast cancer is the most invasive cancer in women worldwide. In the US, about 13% of women, or 1 in 8, will develop breast cancer in their lifetime.

13%

of US women develop breast cancer in their lifetime

Source: American Cancer Society

Treatment

Personalized medicine as a treatment method is increasingly adopted.

There are many ways to treat breast cancer. Nowadays, advances in genomic sequencing, bioinformatics, and data analysis have made the use of personalized medicine increasingly popular.

Personalized Medicines

The treatment of cancer by killing cells with powerful chemicals. Increasingly adopted with advances in genomic sequencing.

Chemotherapy

The treatment of cancer by killing cells with powerful chemicals.

Radiation Therapy

The usage of high-energy rays to destroy cancer cells.

Personalized Medicines

The treatment of cancer by killing cells with powerful chemicals. Increasingly adopted with advances in genomic sequencing.

Hormone Therapy

Blocking hormones that fuel certain types of breast cancer cells.

Immunotherapy

The treatment of cancer by helping the immune system recognize and attack cancer cells.

Sounds good! The problem?

Appropriate personalized medicines are hard to identify,
and by hard, we mean really hard.

Heterogeneity of Tumors

Many Genetic Mutations

Dynamic Evolution of Tumors

High-Throughput Data Processing

Finding Reliable Biomarkers

Extensive Target Validation Required

Limited Therapeutic Window

Tumors Developing Resistance Mechanisms

Patient Stratification Needed

Regulatory Challenges

High Costs of Treatment

Advanced Infrastructure Requirements

Heterogeneity of Tumors

Many Genetic Mutations

Dynamic Evolution of Tumors

High-Throughput Data Processing

Finding Reliable Biomarkers

Extensive Target Validation Required

Limited Therapeutic Window

Tumors Developing Resistance Mechanisms

Patient Stratification Needed

Regulatory Challenges

High Costs of Treatment

Advanced Infrastructure Requirements

That is where ScanCer comes in!

ScanCer is an ATP-FRET probe for high-throughput screening of breast cancer medicines.

Here's how it works.

With how it works in mind, we can now move on to the specifics of ScanCer.

Overview

Go into the technical details of ScanCer.

Visit Our Overview Page